Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models

Virology. 2008 Jun 5;375(2):529-38. doi: 10.1016/j.virol.2008.02.022. Epub 2008 Apr 22.

Abstract

A panel of paired primary virus isolates and envelope pseudoviruses from sixty strains representing six HIV-1 clades was tested for neutralization using pooled, clade-specific plasma in two prominently utilized neutralization platforms: a primary isolate assay using peripheral blood mononuclear cells (PBMC) and a pseudovirus assay using a reporter epithelial cell line. Using the PMBC assay, pairing of the antibody pool against homologous clade viruses generated the highest geometric mean neutralizing antibody titer in 4 out of 6 clades tested, and neutralization patterns showed numerous examples of reciprocal cross-recognition between antibody and viruses of specific clade pairs. In the pseudovirus assay, cross-clade neutralization was more limited, with fewer distinct cross-clade relationships evident. The clade C antibody pool was broadly cross-reactive, neutralizing the greatest number of viruses in both assays. These data highlight the importance of the neutralization assay format employed and suggest that clade C envelopes merit further evaluation for the elicitation of broadly neutralizing antibodies.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • AIDS Vaccines / immunology*
  • Antibody Specificity
  • Cells, Cultured
  • Cross Reactions
  • Disease Outbreaks
  • HIV Antibodies / blood
  • HIV Antibodies / immunology*
  • HIV Infections / immunology*
  • HIV Infections / prevention & control
  • HIV-1 / classification
  • HIV-1 / immunology*
  • HeLa Cells
  • Humans
  • Leukocytes, Mononuclear
  • Neutralization Tests / methods*
  • Neutralization Tests / standards
  • Sensitivity and Specificity

Substances

  • AIDS Vaccines
  • HIV Antibodies